Smith Group Asset Management’s Audentes Therapeutics, Inc BOLD Stock Holding History

Smith Group Asset Management’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,570	Closed	-$94K	–	391
2019 Q4	$94K	Hold	1,570	–	–	﹤0.01%	242
2019 Q3	$44K	Buy	+1,570	New	+$53.6K	﹤0.01%	287

Smith Group Asset Management's BOLD Position: Q1 2020 in Review

Smith Group Asset Management sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 1,570 shares — an estimated $94K sold.

Smith Group Asset Management first reported a position in BOLD in Q3 2019 and held it in 2 quarters. The position peaked at $94K in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Smith Group Asset Management reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Smith Group Asset Management sold 1,570 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $94K.
Smith Group Asset Management first reported a position in Audentes Therapeutics, Inc in Q3 2019 and held it in 2 quarters.
Smith Group Asset Management's Audentes Therapeutics, Inc position peaked at $94K in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Smith Group Asset Management's 13F filing for Q1 2020, filed 12 May 2020.